Published in:
01-10-2012
Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers
Authors:
Antonio Tello-Montoliu, Fabiana Rollini, Bhaloo Desai, Giuseppe Pasqualino, Ronakkumar Patel, Alexandra Santana Sorensen, Kjell S. Sakariassen, Dominick J. Angiolillo
Published in:
Journal of Thrombosis and Thrombolysis
|
Issue 3/2012
Login to get access
Excerpt
Antiplatelet agents are important for the treatment of patients with atherosclerotic disease manifestations. Antiplatelet agents act by inhibiting platelet activation and aggregation processes, which are mediated by several activating factors including thromboxane A2 (TxA
2), adenosine diphosphate (ADP), and thrombin. In particular, TxA
2 induced platelet activation is a pivotal pharmacological target as supported by the undisputable benefit of aspirin in secondary prevention of ischemic events [
1,
2]. …